low-molecular-weight heparin

Phase 3Small molecule

Daiichi Sankyo

low-molecular-weight heparin is one of 193 small molecule programs targeting Adenomyosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

192

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

Venous ThromboembolismRecruiting

Venous ThrombosisActive, not recruiting

HematomaActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Atrial FibrillationActive, not recruiting

COVID-19Active, not recruiting

ESSUnknown status

Anticoagulant TherapyCompleted

Septal DefectUnknown status

AdenomyosisPreclinical

Active, not recruiting

Venous ThromboembolismPhase 3

Recruiting

Venous ThrombosisPreclinical

Active, not recruiting

HematomaPreclinical

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

ESSPreclinical

Unknown status

Anticoagulant TherapyPreclinical

Completed

Septal DefectPreclinical

Unknown status

Showing 10 of 11 indications

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

low-molecular-weight heparin

Daiichi Sankyo

Phase 3

3 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Hip Fracture

NCT07228663

Q3 2028

Post-ApprovalRecruiting

Venous Thromboembolism

NCT06845423

Q4 2028

Recruiting

Extremity

NCT07863115

Q4 2030

Phase 3Recruiting

Venous Thromboembolism

NCT06494878

Clinical

Trials by Indication[1]

Pulmonary Embolism4 trials

Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD

Unknown status·—·Phase 4·NCT01531829·460 enrolled

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown status·UUniversity of Birmingham·Phase 3·NCT04727437·1,466 enrolled

Deferment of Imaging for Pulmonary Embolism

Completed·AAzienda Ospedaliera Universitaria Policlinico·Phase 4·NCT00381511·300 enrolled

Show 1 more trial

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

Terminated·UUniversity Medical Center Groningen·Phase 3·NCT01164046·56 enrolled

Venous Thromboembolism4 trials

Optimal Prophylactic Method of Venous Thromboembolism (VTE)

Unknown status·TThe Catholic University of Korea·Phase 3·NCT01448746·682 enrolled

Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk

Recruiting·UUniversity Hospital, Brest·Phase 4·NCT06845423·2,400 enrolled

Cancer Venous Thromboembolism (VTE)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02073682·1,046 enrolled

Show 1 more trial

The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial

Recruiting·UUniversity of Calgary·Phase 3·NCT06494878·8,805 enrolled

Pneumonia3 trials

Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis

Terminated·TThrombologic ApS·Phase 2·NCT01532544·5 enrolled

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Unknown status·GGrupo de Investigación Clínica en Oncología Radioterapia·N/A·NCT04380818·106 enrolled

D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia

Unknown status·—·Phase 4·NCT04584580·50 enrolled

COVID-193 trials

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Unknown status·—·N/A·NCT05279391·150 enrolled

Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

Completed·QQuovadis Associazione··NCT04393805·744 enrolled

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

Suspended·FFundacion GenesisCare·N/A·NCT04394182·15 enrolled

Portal vein thrombosis3 trials

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

Unknown status·YYangzhou University·Phase 4·NCT02238444·60 enrolled

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

Completed·NNorthern Jiangsu People's Hospital·Phase 4·NCT04645550·120 enrolled

Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection

Completed·YYangzhou University·Phase 4·NCT02247414·124 enrolled

26 more indications

Pregnancy3 trials

Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT03120715·342 enrolled

Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women

Unknown status·SShanghai First Maternity and Infant Hospital··NCT03365466·200 enrolled

Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss

Completed·RRESnTEC, Institute of Research·N/A·NCT06484634·175 enrolled

Low Molecular Weight Heparin2 trials

Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction

Unknown status·WWest China Hospital·N/A·NCT03171727·117 enrolled

Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.

Unknown status·DDr.Vandana Bansal·Phase 3·NCT01924104·400 enrolled

Venous thrombosis2 trials

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

Unknown status·UUniversity of Tennessee·N/A·NCT01029821·100 enrolled

Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards

Unknown status·UUniversity of Roma La Sapienza··NCT03157843·1,000 enrolled

Rivaroxaban2 trials

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

Completed·—·Phase 1/2·NCT03282643·74 enrolled

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02746185·159 enrolled

Sepsis2 trials

A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00049777·2,000 enrolled

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06381661·2,000 enrolled

Anticoagulant Therapy2 trials

Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices

Unknown status·QQilu Hospital of Shandong University··NCT05545475·100 enrolled

Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula

Completed·FFirst Affiliated Hospital of Chongqing Medical University·N/A·NCT04164693·287 enrolled

Prospective1 trial

Prospective Study of BMD and Ca-P Metabolism in RSA Patients: LMWH Use Versus Control

Unknown status·AAimin Zhao··NCT05878574·344 enrolled

Hematoma1 trial

Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy

Completed·KKantonsspital Winterthur KSW··NCT02875717·500 enrolled

Antiphospholipid Syndrome1 trial

AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

Terminated·OOttawa Hospital Research Institute·Phase 1·NCT03100123·1 enrolled

ESS1 trial

Immunosuppressant Regimens for Living Fetuses Study

Unknown status·RRenJi Hospital·N/A·NCT03671174·420 enrolled

Atrial Fibrillation1 trial

Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)

Withdrawn·—··NCT04508855

Growth1 trial

Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.

Completed·FFundació Sant Joan de Déu·Phase 3·NCT03324139·48 enrolled

Adenomyosis1 trial

Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome

Unknown status·NNanjing University·N/A·NCT04741295·70 enrolled

Preeclampsia1 trial

PP13 and Doppler Study to Predict Preeclampsia

Unknown status·—·Phase 2/3·NCT00928213·1,000 enrolled

Spinal Cord Injury1 trial

Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury

Terminated·MMcMaster University·Phase 2·NCT03200613·8 enrolled

Thrombosis1 trial

Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)

Unknown status·RRenJi Hospital·Phase 3·NCT04946929·50 enrolled

Deep Vein Thrombosis1 trial

Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis

Unknown status·AAzienda Ospedaliera Universitaria Policlinico·Phase 4·NCT00450645·300 enrolled

Intracerebral Hemorrhage1 trial

Restart Anticoagulation in Patients With Spontaneous Intracerebral Hemorrhage and Mechanical Heart Valves

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT04450446·100 enrolled

Thromboembolism1 trial

Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism

Unknown status·—··NCT05512702·100 enrolled

Hip Fracture1 trial

Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention

Not yet recruiting·MMcMaster University·Phase 3·NCT07228663·100 enrolled

Septal Defect1 trial

Study of Blood Clotting After Transcatheter Atrial Septal Defect Closure

Unknown status·TThird Military Medical University·N/A·NCT01086046·450 enrolled

Fetal Growth Restriction1 trial

Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment

Unknown status·—·Phase 3·NCT03230162·100 enrolled

Thrombocytopenia1 trial

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Unknown status·QQin Ning·Phase 4·NCT05604859·350 enrolled

Occlusion1 trial

Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization

Completed·—·Phase 4·NCT04196309·60 enrolled

Prophylaxis1 trial

Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients

Unknown status·—··NCT04248348·600 enrolled

Extremity1 trial

Validation of the TRiP-cast Score and Evaluation of Adherence to Preventive Anticoagulant Treatment in Non-Hospitalized Patients With Lower Limb Trauma Requiring Immobilization

Recruiting·UUniversity of Monastir··NCT07863115·1,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 50 trial records for low-molecular-weight heparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — low-molecular-weight heparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for low-molecular-weight heparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Daiichi Sankyo

low-molecular-weight heparin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Q4 2028

Q4 2030

Trials by Indication[1]

Pulmonary Embolism4 trials

Venous Thromboembolism4 trials

Pneumonia3 trials

COVID-193 trials

Portal vein thrombosis3 trials

Pregnancy3 trials

Low Molecular Weight Heparin2 trials

Venous thrombosis2 trials

Rivaroxaban2 trials

Sepsis2 trials

Anticoagulant Therapy2 trials

Prospective1 trial

Hematoma1 trial

Antiphospholipid Syndrome1 trial

ESS1 trial

Atrial Fibrillation1 trial

Growth1 trial

Adenomyosis1 trial

Preeclampsia1 trial

Spinal Cord Injury1 trial

Thrombosis1 trial

Deep Vein Thrombosis1 trial

Intracerebral Hemorrhage1 trial

Thromboembolism1 trial

Hip Fracture1 trial

Septal Defect1 trial

Fetal Growth Restriction1 trial

Thrombocytopenia1 trial

Occlusion1 trial

Prophylaxis1 trial

Extremity1 trial

References

Drug Info

Quick Facts

Related News